They met with management and were 'impressed'. Raised their DCF price target from $65 to $84.
They stated that the meeting left them with these tidbits
- Rheumalogy is just getting started and expected to continue growing
- Lupus is starting and expected to be helped by a research paper due in the fall
- Sarcoidosis launch is expected to see good physician and patient demand
- Dermatology and Eye revenue could top $2B
Also that the execs seem serious about Synacthen and are starting worldwide re-launch, country by country. There are 50 countries they are acquiring the license to market Synacthen in. (Remember, Novartis contracted with Sigma Tau about 5 years ago for Europe and Sigma Tau didn't really cut the mustard for them. Novartis went with Questcor because the big Q will have focus where Sigma just added it to their drug list of things to market.)
Also mentioned that Acthar is now approved in a few countries for some indications and they plan to launch Acthar overseas.
Future Competition seems unlikely and they have a few paragraphs on why with the summary being it would actually take 10 to 12 years for a competitor to launch
The CFO job posting was a split of duties because one guy was handling too much for two jobs with all the growth.
and then of course, they have a write up on what to do with all that cash, the numerous black out periods because of all the deals the last 10 months, and Questcor's ability to now restart that 6M share repurchase.
Mikey, Thanks for sharing. I do not subscribe and deeply appreciate this synopsis of ongoing, robust potential.
Folks, we need to bump this for the next two to three days. This is so encouraging. Jim
Sentiment: Strong Buy
Mikey...this report puts the future of Q into perspective. This is why the stock is a perfect vehicle for long term investing. Short swing trades may make a few bucks but the big money is yet to be realized. As I have reiterated in the past, the indications, present and future are simply "gargantuan". Anyone with a little bit of a scientific background can surely see what the potential is here.
Sentiment: Strong Buy